C
Catherine H Bozio
Researcher at Centers for Disease Control and Prevention
Publications - 25
Citations - 1613
Catherine H Bozio is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 8, co-authored 15 publications receiving 150 citations. Previous affiliations of Catherine H Bozio include National Center for Immunization and Respiratory Diseases & Kaiser Permanente.
Papers
More filters
Journal ArticleDOI
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands,S. Rao,Brian E. Dixon,Patrick K. Mitchell,Malini B. DeSilva,Stephanie A. Irving,Ned Lewis,Karthik Natarajan,Edward Stenehjem,Shaun J. Grannis,Jungmi Han,Charlene McEvoy,Toan C. Ong,Allison L. Naleway,Sara E. Reese,Peter J. Embi,Kristin Dascomb,Nicola P. Klein,E. Griggs,D. Konatham,Anupam B. Kharbanda,Duck-Hye Yang,William F. Fadel,Nancy Grisel,Kristin Goddard,Palak Patel,I-Chia Liao,Rebecca Birch,Nimish Valvi,Sue Reynolds,Julie Arndorfer,Ousseny Zerbo,M. Dickerson,Kempapura Murthy,Jeremiah Williams,Catherine H Bozio,Lenee Blanton,Jennifer R. Verani,Stephanie J. Schrag,Alexandra F. Dalton,Mehiret Wondimu,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Michelle A. Barron,Manjusha Gaglani,Mark Thompson,Bruce Fireman +46 more
TL;DR: VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination, and VE was generally higher for protection against hospitalizations than against ED/UC visits.
Journal ArticleDOI
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
Mark G. Thompson,Edward Stenehjem,Shaun J. Grannis,Sarah Ball,Allison L. Naleway,Toan C. Ong,Malini B. DeSilva,Karthik Natarajan,Catherine H Bozio,Ned Lewis,Kristin Dascomb,Brian E. Dixon,Rebecca J. Birch,Stephanie A. Irving,Suchitra Rao,Elyse O. Kharbanda,Jungmi Han,Sue Reynolds,Kristin Goddard,Nancy Grisel,William F. Fadel,Matthew E Levy,Jill M. Ferdinands,Bruce Fireman,J.A Arndorfer,Nimish R. Valvi,Elizabeth A Rowley,Palak Patel,Ousseny Zerbo,Eric P. Griggs,Rachael M. Porter,Maria Demarco,Lenee Blanton,Andrea Steffens,Yan Zhuang,Natalie Olson,Michelle A. Barron,Pat Shifflett,Stephanie J. Schrag,Jennifer R. Verani,Alicia M Fry,Manjusha Gaglani,Eduardo Azziz-Baumgartner,Nicola P. Klein +43 more
TL;DR: In this article, the effectiveness of the Ad26.COV2.S vaccine against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an emergency department or urgent care clinic visit was evaluated.
Journal ArticleDOI
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark Thompson,Karthik Natarajan,Stephanie A. Irving,Elizabeth Rowley,E. Griggs,Manjusha Gaglani,Nicola P. Klein,Shaun J. Grannis,Malini B. DeSilva,Edward Stenehjem,Sara E. Reese,M. Dickerson,Allison L. Naleway,Jungmi Han,D. Konatham,Charlene McEvoy,S. Rao,Brian E. Dixon,Kristin Dascomb,Ned Lewis,M. Levy,Palak Patel,I-Chia Liao,Anupam B. Kharbanda,Michelle A. Barron,William F. Fadel,Nancy Grisel,Kristin Goddard,Duck-Hye Yang,Mehiret Wondimu,Kempapura Murthy,Nimish Valvi,Julie Arndorfer,Bruce Fireman,M. Dunne,Peter J. Embi,Eduardo Azziz-Baumgartner,Ousseny Zerbo,Catherine H Bozio,Sue Reynolds,Jill M. Ferdinands,Jeremiah Williams,Ruth Link-Gelles,Stephanie J. Schrag,Jennifer R. Verani,Sarah Ball,Toan C. Ong +46 more
TL;DR: The highest estimates of VE against COVID-19-associated ED and UC encounters or hospitalizations during both Delta- and Omicron-predominant periods were among adults who received a third dose of mRNA vaccine, and all unvaccinated persons should get vaccinated as soon as possible.
Journal ArticleDOI
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
Nicola P. Klein,Melissa S. Stockwell,Maria Demarco,Manjusha Gaglani,Anupam B. Kharbanda,Stephanie A. Irving,S. Rao,Shaun J. Grannis,Kristin Dascomb,Kempapura Murthy,Elizabeth Rowley,Alexandra F. Dalton,Malini B. DeSilva,Brian E. Dixon,Karthik Natarajan,Edward Stenehjem,Allison L. Naleway,Ned Lewis,Toan C. Ong,Palak Patel,D. Konatham,Peter J. Embi,Sara E. Reese,Jungmi Han,Nancy Grisel,Kristin Goddard,Michelle A. Barron,M. Dickerson,I-Chia Liao,William F. Fadel,Duck-Hye Yang,Julie Arndorfer,Bruce Fireman,E. Griggs,Nimish Valvi,C. Hallowell,Ousseny Zerbo,Sue Reynolds,Jill M. Ferdinands,Mehiret Wondimu,Jeremiah Williams,Catherine H Bozio,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Stephanie J. Schrag,Mark Thompson,Jennifer R. Verani +46 more
TL;DR: VE against laboratory-confirmed COVID-19-associated hospitalization among children aged 5-11 years was 74% 14-67 days after dose 2, with wide CIs that included zero, and in adolescents aged 16-17 years, VE during the Omicron predominant period increased to 81% ≥7 days after a third booster dose.
Journal ArticleDOI
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
Peter J Embi,Matthew E Levy,Allison L. Naleway,Palak Patel,Manjusha Gaglani,Karthik Natarajan,Kristin Dascomb,Toan C Ong,Nicola P. Klein,I-Chia Liao,Shaun J. Grannis,Jungmi Han,Edward Stenehjem,Margaret M Dunne,Ned Lewis,Stephanie A. Irving,Suchitra Rao,Charlene McEvoy,Catherine H Bozio,Kempapura Murthy,Brian E. Dixon,Nancy Grisel,Duck-Hye Yang,Kristin Goddard,Anupam B Kharbanda,Sue Reynolds,Chandni Raiyani,William F. Fadel,Julie Arndorfer,Elizabeth A Rowley,Bruce Fireman,Jill M. Ferdinands,Nimish R Valvi,Sarah Ball,Ousseny Zerbo,Eric P Griggs,Patrick K. Mitchell,Rachael M. Porter,Salome A Kiduko,Lenee Blanton,Yan Zhuang,Andrea Steffens,Sarah E Reese,Natalie Olson,Jeremiah Williams,Monica Dickerson,Meredith McMorrow,Stephanie J. Schrag,Jennifer R. Verani,Alicia M. Fry,Eduardo Azziz-Baumgartner,Michelle A Barron,Mark G. Thompson,Malini B. DeSilva +53 more
TL;DR: In this paper, the authors evaluated vaccine effectiveness among immunocompromised adults with COVID-19-associated hospitalization, using data from the VISION Network* on hospitalizations among persons aged ≥18 years with CoV-19like illness from 187 hospitals in nine states during January 17-September 5, 2021.